New Information on Surgical MVr in Primary MR - Anelechi Anyanwu

Loading player ... The player requires Flash Player plugin

Case description

Anelechi Anyanwu, MD, and Randy Martin, MD, discuss recent findings about the safety and morbidity findings in over 53,000 patients who underwent surgical mitral valve repair for primary regurgitation over a 6-year period. This information was published in JACC by Dr. Vinay Badhwar. Dr. Anyanwu and Dr. David Adams at Mount Sinai’s Mitral Valve Repair Reference Center have had extensive experience over decades in surgical repair of primary mitral regurgitation. 

Dr. Anyanwu highlights that low 30-day mortality and morbidity, while encouraging, is not a surrogate for quality. He and Dr. Adams feel the quality metrics should be based on procedural success at 30 days, procedural effectiveness at 1 year and durability over 5 years. Dr. Anyanwu also emphasizes the importance of eliminating MR at the initial operative intervention as well as paying attention to treating atrial fibrillation and coexistent tricuspid regurgitation.

Anelechi Anyanwu, MD, Surgical Director, Heart Transplantation and Mechanical Circulatory Support, Vice Chair and Professor, Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai

Randolph P. Martin, MD, Clinical Professor, Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai


tags: primary MVR JACC mitral Anelechi Anyanwu Randy Martin Icahn School of Medicine cardiovascular surgery primary regurgitation surgical mitral valve repair mitral valve surgery CVS video cvs education cvs training cvs video case Surgical MVr surgical technique Primary MR tricuspid regurgitation atrial fibrillation Mount Sinai professional education

This user also sharing


show more